Posts Tagged ‘XTLB’

IMPLOSION ALERT: XTL Biopharma (XTLB)

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) failed to meet primary and secondary endpoints in its Phase IIB study to treat neuropathic pain in diabetes patients.  This looks like the newest biotech zombie.  In only about 15 minutes of normal trading and with the pre-market trading volume, there has been over 12 million shares trading hands.  This [...]

RSS 2.0 |